[go: up one dir, main page]

MX2016010919A - 4-bencilsulfonil-2-butenonitrilo. - Google Patents

4-bencilsulfonil-2-butenonitrilo.

Info

Publication number
MX2016010919A
MX2016010919A MX2016010919A MX2016010919A MX2016010919A MX 2016010919 A MX2016010919 A MX 2016010919A MX 2016010919 A MX2016010919 A MX 2016010919A MX 2016010919 A MX2016010919 A MX 2016010919A MX 2016010919 A MX2016010919 A MX 2016010919A
Authority
MX
Mexico
Prior art keywords
butenenitrile
benzylsulfonyl
pharmaceutically acceptable
solvate
directed
Prior art date
Application number
MX2016010919A
Other languages
English (en)
Inventor
P St Laurent Joseph
s jones Gerald
M Bresse David
a goodrich Scott
Original Assignee
Olatec Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olatec Therapeutics Llc filed Critical Olatec Therapeutics Llc
Publication of MX2016010919A publication Critical patent/MX2016010919A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención está dirigida a una composición farmacéutica que comprende un portador farmacéuticamente aceptable y 4-bencilsulfonil-2-butenonitrilo, o una sal o solvato farmacéuticamente aceptable de esta. La presente invención se dirige a un método para tratar la inflamación, trastornos relacionados con la inflamación, o dolor, por medio de la administración de 4-bencilsulfonil-2-butenonitrilo, o una sal o solvato farmacéuticamente aceptable de éste a un sujeto que lo requiere.
MX2016010919A 2014-02-25 2015-02-23 4-bencilsulfonil-2-butenonitrilo. MX2016010919A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461944527P 2014-02-25 2014-02-25
PCT/US2015/017049 WO2015130595A1 (en) 2014-02-25 2015-02-23 4-benzylsulfonyl-2-butenenitrile

Publications (1)

Publication Number Publication Date
MX2016010919A true MX2016010919A (es) 2016-11-29

Family

ID=54009524

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010919A MX2016010919A (es) 2014-02-25 2015-02-23 4-bencilsulfonil-2-butenonitrilo.

Country Status (5)

Country Link
US (1) US9987246B2 (es)
EP (1) EP3110412B1 (es)
CN (1) CN106102726B (es)
MX (1) MX2016010919A (es)
WO (1) WO2015130595A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7989495B2 (en) * 2002-02-21 2011-08-02 University Of Utah Research Foundation Compositions and methods for inhibiting NF-κB mediated tumorigenicity and adhesion dependent survival of cancer cells
CN102077393B (zh) * 2008-07-04 2014-01-08 索尼公司 二次电池和电子装置
CA2875054A1 (en) * 2012-06-05 2013-12-12 Olatec Industries Llc Pharmaceutical composition for treating inflammation and pain
US9481644B2 (en) 2012-06-05 2016-11-01 Olatec Therapeutics Llc Pharmaceutical composition comprising omega-(arylsulfonyl)alkylnitrile
EP2854784B1 (en) * 2012-06-05 2019-12-04 Olatec Therapeutics LLC Method for treating skin inflammatory diseases
US20150182488A1 (en) 2012-09-11 2015-07-02 Olatec Industries Llc Methods for treating inflammation and pain
WO2014043144A1 (en) * 2012-09-11 2014-03-20 Olatec Industries Llc Methods for treating inflammation and pain
US9440916B2 (en) * 2013-09-26 2016-09-13 Olatec Therapeutics Llc 3, 4-bis-benzylsulfonylbutyronitrile and its pharmaceutical use
US9999610B2 (en) 2013-10-01 2018-06-19 Olatec Therapeutics Llc Pharmaceutical use of 3-benzylsulfonylpropionitrile
US9522878B2 (en) * 2013-10-07 2016-12-20 Olatec Therapeutics Llc 4-methylsulfonyl-2-butenenitrile and its pharmaceutical use

Also Published As

Publication number Publication date
US20160361286A1 (en) 2016-12-15
CN106102726B (zh) 2019-04-23
WO2015130595A1 (en) 2015-09-03
EP3110412A1 (en) 2017-01-04
CN106102726A (zh) 2016-11-09
US9987246B2 (en) 2018-06-05
EP3110412A4 (en) 2017-10-25
EP3110412B1 (en) 2018-10-31

Similar Documents

Publication Publication Date Title
GB2541571A (en) Pharmaceutical compositions
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
PH12017500933A1 (en) Sublingual administration of riluzole
PH12017500934A1 (en) Sublingual formulation of riluzole
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
TW201613578A (en) Pharmaceutical combinations
PH12016502352A1 (en) Pharmaceutical composition
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
NZ722600A (en) Methods of treating mild brain injury
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
TN2019000032A1 (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2022014763A (es) Composiciones de grapiprant y metodos para usar las mismas.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
PH12017501979A1 (en) Pharmaceutical compound
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX368641B (es) Compuestos para el tratamiento de inflamación y dolor.
MX368640B (es) Composición farmacéutica para tratar inflamación y dolor.
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.
MX2016002139A (es) Composicion farmaceutica y uso del (2-cianoetil)fosfonato de dietilo.
PH12020500472A1 (en) Autotaxin inhibitor compounds
IN2014DE00822A (es)

Legal Events

Date Code Title Description
FG Grant or registration